A case of ustekinumab-induced sclerouveitis

Kristen S Godwin; Mariam Mathai; Brian K Do

doi:10.1016/j.ajoc.2022.101331

A case of ustekinumab-induced sclerouveitis

Am J Ophthalmol Case Rep. 2022 Jan 31:25:101331. doi: 10.1016/j.ajoc.2022.101331. eCollection 2022 Mar.

Authors

Kristen S Godwin¹, Mariam Mathai², Brian K Do²

Affiliations

¹ Medstar Georgetown/ Washington Hospital Center Department of Ophthalmology, 110 Irving St NW, Washington, D.C, 20010, USA.
² The Retina Group of Washington, 8270 Willow Oaks Corporate Drive, 6th Floor, Fairfax, VA, 22031, USA.

Abstract

Purpose: Biologics have proven to be essential therapeutic agents in immune-mediated systemic diseases. Ophthalmologic adverse effects have been reported in the use of more traditional agents, such as TNF-α inhibitors, but there are limited data on ocular side effects associated with the newer generation of biologics.

Observations: In this report, we present a case of a suspected ustekinumab-associated recurrent sclerouveitis.

Conclusions: To the best of our knowledge, this is the first reported case of this type seen with ustekinumab injections. Our goal is to add to the existing literature in order to better understand the mechanism and management of this condition.

Keywords: Scleritis; Ustekinumab; Uveitis.

Publication types

Case Reports